Free Trial
→ My next big call (under $1) (From Crypto 101 Media) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
NVLN
Novelion Therapeutics Inc,
C$0.00
C$10.68
▼
C$16.35
C$251.80MN/A3,220 shs3,639 shs
AXS Cannabis ETF stock logo
THCX
AXS Cannabis ETF
$16.60
$16.60
$14.90
▼
$25.40
$141.07M1.7115,071 shsN/A
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
$3.19
-2.6%		$4.23
$3.16
▼
$18.40
$433.80M1.914.23 million shs2.30 million shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
NVLN
Novelion Therapeutics Inc,
0.00%0.00%0.00%0.00%0.00%
AXS Cannabis ETF stock logo
THCX
AXS Cannabis ETF
0.00%0.00%0.00%0.00%0.00%
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
-2.68%-13.49%-18.66%-25.34%-80.65%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
NVLN
Novelion Therapeutics Inc,
C$0.00
C$10.68
▼
C$16.35
C$251.80MN/A3,220 shs3,639 shs
AXS Cannabis ETF stock logo
THCX
AXS Cannabis ETF
$16.60
$16.60
$14.90
▼
$25.40
$141.07M1.7115,071 shsN/A
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
$3.19
-2.6%		$4.23
$3.16
▼
$18.40
$433.80M1.914.23 million shs2.30 million shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
NVLN
Novelion Therapeutics Inc,
0.00%0.00%0.00%0.00%0.00%
AXS Cannabis ETF stock logo
THCX
AXS Cannabis ETF
0.00%0.00%0.00%0.00%0.00%
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
-2.68%-13.49%-18.66%-25.34%-80.65%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
NVLN
Novelion Therapeutics Inc,
0.00
N/AN/AN/A
AXS Cannabis ETF stock logo
THCX
AXS Cannabis ETF
2.01
Hold$16.60N/A
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
2.38
Hold$5.9084.66% Upside

Current Analyst Ratings Breakdown

Latest NVLN, THCX, and TLRY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/9/2026
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetHold$4.50 ➝ $4.00
10/8/2026
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E+) ➝ Sell (D-)
10/5/2026
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
TD logo
TD
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$4.70 ➝ $4.50
9/29/2026
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeHold ➝ Strong Sell
9/21/2026
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D-) ➝ Sell (E+)
9/21/2026
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
ATB Cormark Capital Markets logo
ATB Cormark Capital Markets
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetHold$8.00 ➝ $6.00
8/24/2026
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E+) ➝ Sell (D-)
8/7/2026
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
7/31/2026
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
TD Securities logo
TD Securities
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeStrong-Buy
7/14/2026
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$7.00 ➝ $5.00
(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
NVLN
Novelion Therapeutics Inc,
N/AN/AN/AN/AN/AN/A
AXS Cannabis ETF stock logo
THCX
AXS Cannabis ETF
N/AN/AN/AN/AN/AN/A
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
$915.45M0.48N/AN/A$11.80 per share0.27
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
NVLN
Novelion Therapeutics Inc,
N/AN/AN/AN/AN/AN/AN/AN/AN/A
AXS Cannabis ETF stock logo
THCX
AXS Cannabis ETF
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
-$121.40M-$1.40N/AN/AN/A-16.91%-10.39%-7.38%N/A

Latest NVLN, THCX, and TLRY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/8/2026Q1 2027
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
-$0.1814-$0.02+$0.1614-$0.32$266.26 million$257.15 million
7/28/2026Q4 2026
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
-$0.0120-$0.43-$0.4180-$0.43$246.30 million$281.71 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
NVLN
Novelion Therapeutics Inc,
N/AN/AN/AN/AN/A
AXS Cannabis ETF stock logo
THCX
AXS Cannabis ETF
$0.724.34%N/AN/AN/A
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
NVLN
Novelion Therapeutics Inc,
N/AN/AN/A
AXS Cannabis ETF stock logo
THCX
AXS Cannabis ETF
N/AN/AN/A
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
0.17
1.88
1.11

Institutional Ownership

CompanyInstitutional Ownership
NVLN
Novelion Therapeutics Inc,
N/A
AXS Cannabis ETF stock logo
THCX
AXS Cannabis ETF
N/A
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
9.35%

Insider Ownership

CompanyInsider Ownership
NVLN
Novelion Therapeutics Inc,
N/A
AXS Cannabis ETF stock logo
THCX
AXS Cannabis ETF
N/A
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
1.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
NVLN
Novelion Therapeutics Inc,
10918.93 millionN/ANot Optionable
AXS Cannabis ETF stock logo
THCX
AXS Cannabis ETF
N/A8.50 millionN/ANot Optionable
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
3,595136.20 million134.03 millionOptionable

Recent News About These Companies

Tilray Brands (NASDAQ:TLRY) Stock Price Down 5.1% Following Analyst Downgrade
October 14 at 1:21 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31117120
Tilray Brands (NASDAQ:TLRY) Stock Price Down 2.7% - Should You Sell?
October 13 at 5:39 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-tilray-brands-nasdaq-tlry-stock-price-down-27-should-you-sell-2026-10-13/
Tilray Medical Gains Approval For In-House Quality Testing At Portugal Facility
October 13 at 3:04 PM  |  rttnews.comhttps://www.rttnews.com/3698521/tilray-medical-gains-approval-for-in-house-quality-testing-at-portugal-facility.aspx
Tilray Medical's Portugal Lab Granted Approval for In-House Testing
October 13 at 3:04 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/tilray-medical-apos-portugal-lab-112438275.html
Tilray Medical Strengthens Global Medical Cannabis Supply Chain with Approval to Bring Critical EU-GMP Quality Testing In-House, Accelerating Product Release Across Regulated ...
October 13 at 3:04 PM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/GlobeNewswire/36977806/tilray-medical-strengthens-global-medical-cannabis-supply-chain-with-approval-to-bring-critical-eu-gmp-quality-testing-in-house-accelerating-product-release-across-regulated-global-markets/
Cannabis Stocks To Research - October 13th
October 13 at 12:02 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/list-cannabis-stocks-to-research-october-13th-2026-10-13/
Tilray Medical Strengthens Global Medical Cannabis Supply Chain with Approval to Bring Critical EU-GMP Quality Testing In-House, Accelerating Product Release Across Regulated Global Markets
October 13 at 10:03 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/tilray-medical-strengthens-global-medical-110000461.html
Tilray Medical Strengthens Global Medical Cannabis Supply Chain with Approval to Bring Critical EU-GMP Quality Testing In-House, Accelerating Product Release Across Regulated Global Markets
October 13 at 7:11 AM  |  financialpost.comF
BrewDog Acquisition Boosts Tilray's Q1 Performance
October 13 at 2:00 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4953640-brewdog-acquisition-boosts-tilrays-stock-q1-performance
Is Tilray Brands (NASDAQ:TLRY) Ready for Its Next Market Test?
October 12 at 5:24 PM  |  kalkinemedia.comK
3 Huge Red Flags From Tilray's Q1 Earnings Report
October 12 at 5:24 PM  |  fool.comhttps://www.fool.com/investing/2026/10/12/3-huge-red-flags-from-tilray-s-q1-earnings-report/
Tilray Q1: Not Looking Good, Remains A 'Hold'
October 12 at 5:00 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4953597-tilray-q1-not-looking-good-remains-a-hold
Tilray Brands (NASDAQ:TLRY) Stock Falls 5.1% After Analyst Downgrade
October 12 at 4:59 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-tilray-brands-nasdaq-tlry-stock-falls-51-after-analyst-downgrade-2026-10-12/
Tilray: why this analyst just cut his price target
October 12 at 12:23 PM  |  cantechletter.comC
Cannabis Stocks To Follow Now - October 9th
October 12 at 3:34 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31109462
Cannabis Stocks To Watch Today - October 11th
October 11 at 12:00 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/list-cannabis-stocks-to-watch-today-october-11th-2026-10-11/
Tilray (NASDAQ: TLRY) lifts revenue 23% as beverage sales jump on BrewDog
October 11 at 8:32 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31107961
Tilray Brands (NASDAQ:TLRY) Stock Price Down 1.4% Following Analyst Downgrade
October 11 at 2:24 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31107081
Canaccord Genuity Group Has Lowered Expectations for Tilray Brands (NASDAQ:TLRY) Stock Price
October 11 at 1:37 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31106848
Canopy Growth vs. Tilray Brands: Which Healthcare Stock Is a Better Buy in 2026?
October 10, 2026  |  fool.comhttps://www.fool.com/coverage/better-buy/2026/10/10/canopy-growth-vs-tilray-brands-which-healthcare-stock-is-a-better-buy-in-2026/
TD Cowen Sticks to Their Buy Rating for Tilray (TLRY)
October 10, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/TLRY/pressreleases/5689313/td-cowen-sticks-to-their-buy-rating-for-tilray-tlry/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Micron, Coherent and Tower Semiconductor: 3 Stocks Built on AI's Bottlenecks
NVIDIA Just Named AI's Next Bottleneck—And These 3 Stocks Sit Right In It
By Bridget Bennett | September 20, 2026
Stacks of coins rising on a desk beside a computer with an upward stock chart, with a blurred city skyline behind.
3 Dividend Kings to Buy While They’re Still Beaten Down
By Thomas Hughes | September 14, 2026
Shopping bags sit on a polished marble floor inside an upscale retail store or shopping mall.
3 Luxury Consumer Brands to Watch in a Beaten-Down Sector
By Nathan Reiff | September 16, 2026
Computer monitor with a red plunging chart arrow on a desk, symbolizing software stocks selloff amid AI fears.
MarketBeat's Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks Risky
By Thomas Hughes | September 15, 2026
Tilray logo overlaid on a cannabis cultivation and processing facility with plants and packaged product jars.
Tilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform
By Jeffrey Neal Johnson | October 9, 2026

Novelion Therapeutics Inc, TSE:NVLN

Novelion Therapeutics Inc, formerly QLT Inc., is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development. The Company holds a portfolio of products through its subsidiary, Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. The Company's portfolio of products include MYALEPT and JUXTAPID. The Company is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes.

AXS Cannabis ETF stock logo

AXS Cannabis ETF NYSEARCA:THCX

$16.60 0.00 (0.00%)
As of 03/1/2024

The Cannabis ETF (THCX) is an exchange-traded fund that is based on the AXS Cannabis index. The fund tracks an index of legal cannabis companies selected and weighted by market capitalization. The fund primarily holds North American companies but may also invest in other countries. THCX was launched on Jul 9, 2019 and is managed by AXS Investments.

Tilray Brands stock logo

Tilray Brands NASDAQ:TLRY

$3.18 -0.09 (-2.60%)
As of 01:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas